Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $863,876 | $694,951 | $451,246 | $576,885 |
| - Cash | $135,156 | $149,569 | $212,315 | $297,263 |
| + Debt | $2,714 | $574,495 | $564,636 | $201,910 |
| Enterprise Value | $731,434 | $1,119,877 | $803,567 | $481,532 |
| Revenue | $49,504 | $39,503 | $28,519 | $29,664 |
| % Growth | 25.3% | 38.5% | -3.9% | – |
| Gross Profit | $43,314 | $34,465 | $24,795 | $25,849 |
| % Margin | 87.5% | 87.2% | 86.9% | 87.1% |
| EBITDA | -$13,709 | -$58,120 | -$76,068 | -$55,665 |
| % Margin | -27.7% | -147.1% | -266.7% | -187.7% |
| Net Income | -$29,973 | -$75,810 | -$94,316 | -$74,451 |
| % Margin | -60.5% | -191.9% | -330.7% | -251% |
| EPS Diluted | -0.41 | -1.05 | -1.31 | -1.05 |
| % Growth | 61% | 19.8% | -24.8% | – |
| Operating Cash Flow | -$14,115 | -$62,729 | -$84,930 | -$63,456 |
| Capital Expenditures | $0 | -$97 | -$18 | -$5 |
| Free Cash Flow | -$14,115 | -$62,729 | -$84,948 | -$63,461 |